Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506812 | 0.97 | FKBP1A (0.59) | FKBP1AL3MBTL1 | |
| SCHEMBL7220517 | 0.97 | FKBP1A (0.59) | FKBP1AL3MBTL1 | |
| SCHEMBL7220625 | 0.86 | FKBP1A (0.53) | FKBP1ANPSR1 | |
| SCHEMBL7503898 | 0.86 | FKBP1A (0.53) | FKBP1ANPSR1 | |
| SCHEMBL7220384 | 0.86 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL7507953 | 0.86 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL7226997 | 0.84 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL7227001 | 0.84 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL7220717 | 0.81 | L3MBTL1 (0.61) | FKBP1AL3MBTL1ALDH1A1NPSR1KMT2A | |
| SCHEMBL7220712 | 0.81 | L3MBTL1 (0.61) | FKBP1AL3MBTL1ALDH1A1NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544987-B2 | Pyrrolidine or piperidine sulfonyl compounds; stimulate neurite outgrowth in nerve cells leading to nerve regeneration for treatment of hair loss, memory loss or vision disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | NGF, GAP43, BDNF | FKBP1A 4192/4885L3MBTL1 4040/4885ALDH1A1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.